Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01403402 · ClinicalTrials.gov registry record

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

A clinical trial of Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency and Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), sponsored by Cure CMD.

Recruiting
Registry status
4,000
Enrollment target
1
Study location

NCT01403402 is a study of Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency and Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy) that is actively recruiting participants, run by Cure CMD. The registered enrollment target is 4,000 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01403402, a study of Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency and Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), is actively recruiting participants, sponsored by Cure CMD.

RECRUITING
Registry status
4,000 participants
Enrollment target
1
Study location

Study Summary

The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a longitudinal 10 year study to identify and trend care parameters, adverse events in the congenital muscle diseases using the Congenital Muscle Disease International Registry (CMDIR) to acquire necessary data for adverse event calculations (intake survey and medical records curation). To support this study and become a participant, we ask that you register in the CMDIR. You can do this by visiting www.cmdir.org. There is no travel required. The registry includes affected individuals with congenital muscular dystrophy, congenital myopathy, and congenital myasthenic syndrome and registers through the late onset spectrum for these disease groups. The CMDIR was created to identify the global congenital muscle disease population for the purpose of raising awareness, standards of care, clinical trials and in the future a treatment or cure. Simply put, we will not be successful in finding a treatment or cure unless we know who the affected individuals are, what the diagnosis is and how the disease is affecting the individual. Registering in the CMDIR means that you will enter demographic information and complete an intake survey. We would then ask that you provide records regarding the diagnosis and treatment of CMD, including genetic testing, muscle biopsy, pulmonary function testing, sleep studies, clinic visit notes, and hospital discharge summaries. Study hypothesis: 1. To use patient and proxy reported survey answers and medical reports to build a longitudinal care and outcomes database across the congenital muscle diseases. 2. To generate congenital muscle disease subtype specific adverse event rates and correlate with key care parameters.

Study Locations (1)

California

  • Congenital Muscle Disease International Registry (www.cmdir.org) - Lakewood

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2009-09
Est. Completion 2029-09

Sponsor

Cure CMD

3 total trials

What the Registry Record Tells You About NCT01403402

The ClinicalTrials.gov registry entry for NCT01403402 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cure CMD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency appearing as the primary indexed condition, and to 0 interventions.

NCT01403402 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01403402 about?

NCT01403402 is a clinical study titled "Congenital Muscle Disease Study of Patient and Family Reported Medical Information". The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a longitudinal 10 year study to identify and trend care parameters, adverse events in the congenital muscle diseases using the Congenital Muscle Disease International Registry (CMDIR) to acquire necessary data for ad...

What is the current status of trial NCT01403402?

This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2009-09. Estimated completion is 2029-09.

What conditions does trial NCT01403402 study?

This clinical trial studies the following conditions: Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C)).

Who is sponsoring clinical trial NCT01403402?

This trial is sponsored by Cure CMD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01403402 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.